P A Singleton1, T Mirzapoiazova2, R Hasina3, R Salgia3, J Moss4. 1. Department of Medicine, Section of Pulmonary and Critical Care, Department of Anesthesia and Critical Care and psinglet@medicine.bsd.uchicago.edu. 2. Department of Medicine, Section of Pulmonary and Critical Care. 3. Section of Hematology/Oncology, Pritzker School of Medicine, The University of Chicago, Chicago, IL 60637, USA. 4. Department of Anesthesia and Critical Care and.
Abstract
BACKGROUND: We and others have previously demonstrated that the μ-opioid receptor (MOR) is overexpressed in several human malignancies. There is a seven-fold increase in MOR in cell lines of human lung cancer. In animal models, overexpression of MOR promotes tumour growth and metastasis. We, therefore, examined whether MOR expression is increased in metastatic lung cancer. METHODS: In this study, we examined the association between MOR expression and metastasis in archived biopsy samples from patients with lung cancer. Paraffin-embedded patient material was stained using MOR antibody and scored qualitatively by two independent pathologists using a four-point scale. RESULTS: In human lung cancer and normal adjacent lung samples obtained from 34 lung cancer patients, MOR expression was increased significantly in cancer samples from patients with lung cancer compared with adjacent control tissue (P=0.0242). When the samples from patients with metastatic lung cancer were separated from the cohort of the total number of patients with lung cancer, we observed an approximately two-fold increase in MOR expression (P=0.0013). CONCLUSIONS: The association between the expression of MOR and the progression of the tumour is consistent with the hypothesis of a direct effect of MOR on cancer progression.
BACKGROUND: We and others have previously demonstrated that the μ-opioid receptor (MOR) is overexpressed in several humanmalignancies. There is a seven-fold increase in MOR in cell lines of humanlung cancer. In animal models, overexpression of MOR promotes tumour growth and metastasis. We, therefore, examined whether MOR expression is increased in metastatic lung cancer. METHODS: In this study, we examined the association between MOR expression and metastasis in archived biopsy samples from patients with lung cancer. Paraffin-embedded patient material was stained using MOR antibody and scored qualitatively by two independent pathologists using a four-point scale. RESULTS: In humanlung cancer and normal adjacent lung samples obtained from 34 lung cancerpatients, MOR expression was increased significantly in cancer samples from patients with lung cancer compared with adjacent control tissue (P=0.0242). When the samples from patients with metastatic lung cancer were separated from the cohort of the total number of patients with lung cancer, we observed an approximately two-fold increase in MOR expression (P=0.0013). CONCLUSIONS: The association between the expression of MOR and the progression of the tumour is consistent with the hypothesis of a direct effect of MOR on cancer progression.
Authors: Aristomenis K Exadaktylos; Donal J Buggy; Denis C Moriarty; Edward Mascha; Daniel I Sessler Journal: Anesthesiology Date: 2006-10 Impact factor: 7.892
Authors: Rose Christopherson; Kenneth E James; Mara Tableman; Prudence Marshall; Frank E Johnson Journal: Anesth Analg Date: 2008-07 Impact factor: 5.108
Authors: John R Lever; Emily A Fergason-Cantrell; Terry L Carmack; Lisa D Watkinson; Fabio Gallazzi Journal: Nucl Med Biol Date: 2019-03-07 Impact factor: 2.408
Authors: John Pang; Kathryn R Tringale; Viridiana J Tapia; William J Moss; Megan E May; Timothy Furnish; Linda Barnachea; Kevin T Brumund; Assuntina G Sacco; Robert A Weisman; Quyen T Nguyen; Jeffrey P Harris; Charles S Coffey; Joseph A Califano Journal: JAMA Otolaryngol Head Neck Surg Date: 2017-12-01 Impact factor: 6.223
Authors: J Nguyen; K Luk; D Vang; W Soto; L Vincent; S Robiner; R Saavedra; Y Li; P Gupta; K Gupta Journal: Br J Anaesth Date: 2014-05-26 Impact factor: 9.166